Early responses of the STAT3 pathway to platinum drugs are associated with cisplatin resistance in epithelial ovarian cancer

Cisplatin resistance remains one of the major obstacles when treating epithelial ovarian cancer. Because oxaliplatin and nedaplatin are effective against cisplatin-resistant ovarian cancer in clinical trials and signal transducer and activator of transcription 3 (STAT3) is associated with cisplatin...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheng, W.J., Jiang, H., Wu, D.L., Zheng, J.H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Associação Brasileira de Divulgação Científica 2013
Materias:
Biomedical Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3854422/
https://www.ncbi.nlm.nih.gov/pubmed/23969971
http://dx.doi.org/10.1590/1414-431X20133003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3854422/
https://www.ncbi.nlm.nih.gov/pubmed/23969971
http://dx.doi.org/10.1590/1414-431X20133003

Ejemplares similares